Drugs / LTX-109
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04756336 | Mar → Jul 2021 | hidradenitis suppurativa | Pharma Holdings AS | Completed | No outcome recorded |
| Phase 1/2 | NCT04767321 | Feb → Mar 2021 | — | Pharma Holdings AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01158235 | May 2010 → Apr 2011 | — | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04854928 | May 2021 → Feb 2022 | COVID-19 | Pharma Holdings AS | Unknown | No outcome recorded |
| Phase 2 | NCT01803035 | Feb 2013 → Mar 2014 | impetigo | Lytix Biopharma AS | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05889351 Comparator | Sep → Oct 2022 | — | Pharma Holdings AS | Completed | No outcome recorded |
| Phase 2 | NCT01223222 Comparator | Sep 2010 → Feb 2011 | atopic eczema, gram-positive bacterial infections | Lytix Biopharma AS | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTX-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04767321 ↗ |
| Known as | Voxvoganan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1817968 ↗ |
| Modality | Peptide | “LTX-109 (Lytixar™), a lytic peptide designed to kill bacterias quickly and efficient.” NCT01158235 ↗ |
| Route | Intranasal | “Intranasal treatment of S. aureus with LTX-109 is safe and reduces the bacterial load already after a single day of treatment.” PMID 25331699 ↗ Oct 2014 |